Biotechnology · Paramus, New Jersey, United States
$5.69
+3.78% (+$0.21)2026-04-08
EPS$-0.20
Market Cap$269.4M
Price Performance
Historical data including institutional events
Loading price data...
Company Profile
A
Alex Yang
CEO & Executive Director
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders.
Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
The company was founded in 2014 and is based in Paramus, New Jersey.